Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation

Ellen K Ritchie, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Irina Pivneva, PhD, Karen Habucky, PhD, Briana Ndife, MPH, George J Joseph, BPharm, MS, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 3396.

https://doi.org/10.1182/blood.V130.Suppl_1.3396.3396

Published: 2017

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Evaluation of the Correlation between Response and Duration of Treatment in a Phase 2 Study of Pracinostat Plus Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Ehab Atallah, MD, Bruno C Medeiros, MD, Samer Khaled, MD, Mrinal M. Patnaik, MDMBBS, Riccardo Spezia, Elena Palmesino, PhD, Guillermo Garcia-Manero, MD

Blood (2017) 130 (Supplement 1): 1358.

https://doi.org/10.1182/blood.V130.Suppl_1.1358.1358

Published: 2017

Journal Articles

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, Rebecca B. Klisovic, MD, Wendy Stock, MD, David Ungar, MD, Amer M. Zeidan, MD, Ehab Atallah, MD, James McCloskey, MD, Leonard Heffner, MD, Benjamin Tomlinson, MD, Hagop M. Kantarjian, MD, Shui He, PhD, Joseph Boni, PhD, Matthew J. Wieduwilt

Blood (2017) 130 (Supplement 1): 1321.

https://doi.org/10.1182/blood.V130.Suppl_1.1321.1321

Published: 2017

Journal Articles

Successful Implementation of a Blood Management Program for Patients with Hematologic Malignancies

Kristen Corrao, MD, Kathleen Hemauer, MD, Tina Curtis, DNP, MBA, RN, NEA-BC, Dave Atkinson, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Jerome Gottschall, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2160.

https://doi.org/10.1182/blood.V130.Suppl_1.2160.2160

Published: 2017

Journal Articles

Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States

Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2575.

https://doi.org/10.1182/blood.V130.Suppl_1.2575.2575

Published: 2017

Journal Articles

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Aaron D Goldberg, MD, Martin S. Tallman, MD, Melhem M Solh, MD, David Ungar, MD, David A. Rizzieri, MD, Roland B. Walter, MD PhD, Alexander I Spira, MD, Ki-Young Chung, MD, Wendy Stock, MD, Shui He, PhD, Joseph Boni, PhD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2662.

https://doi.org/10.1182/blood.V130.Suppl_1.2662.2662

Published: 2017

Journal Articles

Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States

Guru Subramanian Guru Murthy, MBBS, Ravi Narra, MD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, Laura C. Michaelis, MD, Ehab Atallah, MD

Blood (2017) 130 (Supplement 1): 2578.

https://doi.org/10.1182/blood.V130.Suppl_1.2578.2578

Published: 2017

Journal Articles

Results from the U.S. Life after Stopping TKIs (LAST) Study

Blood (2017) 130 (Supplement 1): 2903.

https://doi.org/10.1182/blood.V130.Suppl_1.2903.2903

Published: 2017

Journal Articles

Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals

Adam Levin, MD, Ariel Kleman, MD, Lisa Rein, MS, Sergey Tarima, PhD, Laura C Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Parameswaran Hari, MBBS, MD MRCP, Ehab Atallah, MD, Binod Dhakal, MD MS

Blood (2016) 128 (22): 2784.

https://doi.org/10.1182/blood.V128.22.2784.2784

Published: 2016

Journal Articles

Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States

Guru Subramanian Guru Murthy, MD, Binod Dhakal, MDMS, Vijaya R. Bhatt, MD, Paulette Mehta, MD, Patrick C. Foy, MD, Laura C Michaelis, MD, Karen B. Carlson, MD PhD, Ehab Atallah, MD

Blood (2016) 128 (22): 3992.

https://doi.org/10.1182/blood.V128.22.3992.3992

Published: 2016

Journal Articles

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Guillermo Garcia Manero, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, MD, Mrinal M Patnaik, MBBS, Olatoyosi Odenike, MD, Hamid Sayar, MD, Mohan Tummala, Prapti A. Patel, MD, Richard G. Ghalie, MD, Bruno C. Medeiros, MD

Blood (2016) 128 (22): 100.

https://doi.org/10.1182/blood.V128.22.100.100

Published: 2016

Journal Articles

Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Ehab Atallah, MD, Laura C Michaelis, MD, Karen B. Carlson, MD PhD, Anita D'Souza, MBBS, MD, Timothy S. Fenske, MD, Marcelo C. Pasquini, MD, Mehdi Hamadani, MD, Arielle Baim, Jessica Guhl, Hari Parameswaran, MD

Blood (2016) 128 (22): 5192.

https://doi.org/10.1182/blood.V128.22.5192.5192

Published: 2016

Journal Articles

Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies

Binod Dhakal, MD, Sridevi Ramalingam, MD, Jamie Shuff, MD, Narendranath Epperla, MD, Lisa Rein, MS, Anjishnu Banerjee, PhD, Malika Siker, MD, Paul R. Hosking, MD, Parameswaran Hari, MD MRCP, MS, Anita D'Souza, MBBS, MD, Ehab Atallah, MD, Beth Erisckson, MD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2015) 126 (23): 2711.

https://doi.org/10.1182/blood.V126.23.2711.2711

Published: 2015

Journal Articles

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Ehab Atallah, MD, Mary M. Horowitz, MD MS, Brent Logan, PhD, Min Chen, MS, Michael J. Boo, JD, Corey S Cutler, MD MPH, Joachim Deeg, MD, James L. Gajewski, MD, Dennis L. Confer, MD, Stephanie Farnia, MPH, Peter Greenberg, MD, Erica Warlick, MD, Daniel Weisdorf, MD, J. Douglas Rizzo, MD

Blood (2015) 126 (23): 193.

https://doi.org/10.1182/blood.V126.23.193.193

Published: 2015

Journal Articles

Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML)

Robert Schneidewend, DO, MS, Karen B. Carlson, MD PhD, Ehab Atallah, MD, Laura C. Michaelis, MD, Paul R. Hosking, MD, Parameswaran Hari, MD MRCP, MS, Mehdi Hamadani, MD, Anita D'Souza, MBBS, MD, Timothy S. Fenske, MD, Marcelo C. Pasquini, MD, Christopher R. Chitambar, MD, Renju V. Raj, MBBS, Kimberli Johnston, PA, Amber Essenmacher, PA, Felicia Zook, PharmD

Blood (2015) 126 (23): 4954.

https://doi.org/10.1182/blood.V126.23.4954.4954

Published: 2015

Journal Articles

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, Mrinal M Patnaik, MBBS, Todd A Butler, Carla Ashby, Bruno C. Medeiros, MD

Blood (2015) 126 (23): 453.

https://doi.org/10.1182/blood.V126.23.453.453

Published: 2015

Journal Articles

Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, MD MS, Megan Othus, PhD, Alan F. List, MD, Olatoyosi Odenike, MD, Richard M. Stone, MD, Steven D. Gore, MD, Mark R Litzow, MD, Rena Buckstein, MD FRCPC, Min Fang, MD PhD, Diane Roulston, PhD, Clara D. Bloomfield, MD, Yanming Zhang, MD, Mario R. Velasco, MD, Rakesh Gaur, MD MPH, Ehab Atallah, MD, Eyal C. Attar, MD, Frederick R Appelbaum, MD, Harry P. Erba, MD PhD

Blood (2015) 126 (23): 908.

https://doi.org/10.1182/blood.V126.23.908.908

Published: 2015

Journal Articles

Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Ehab Atallah, MD, Olatoyosi Odenike, MD, Bruno C Medeiros, Jorge E. Cortes, MD, Vanessa Esquibel, Steven Cha, MD, Samer K Khaled, MD

Blood (2014) 124 (21): 947.

https://doi.org/10.1182/blood.V124.21.947.947

Published: 2014

Journal Articles

A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, MD MS, Megan Othus, PhD, Alan F. List, MD, Olatoyosi Odenike, MD, Richard M. Stone, MD, Steven D. Gore, MD, Mark R. Litzow, MD, Rena Buckstein, MD, Mario r Velasco, MD, Rakesh Gaur, MD, Ehab Atallah, MD, Eyal Attar, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD

Blood (2014) 124 (21): LBA-5.

https://doi.org/10.1182/blood.V124.21.LBA-5.LBA-5

Published: 2014

NARROW

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Evaluation of the Correlation between Response and Duration of Treatment in a Phase 2 Study of Pracinostat Plus Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Successful Implementation of a Blood Management Program for Patients with Hematologic Malignancies

Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States

Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia

Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States

Results from the U.S. Life after Stopping TKIs (LAST) Study

Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals

Incidence and Overall Survival of Therapy Related Myeloid Neoplasm in United States

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Phase I Study of Combination Chemotherapy Plus Ixazomib in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML)

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)

A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only